



FibroScan® Referral

Victorian Infectious Diseases Service (VIDS) The Royal Melbourne Hospital Grattan Street, Parkville, VIC 3050

To refer please use the RMH Specialist Clinics referral fax: 03 9342 4234

Insert patier	nt label OF	R enter p	atient details	here:
Name:				
UR:				
D.O.B:	/	/	Sex M	F
Address:				
Suburb:			Postcode:_	
Phone:				

Liver Biopsy ☐ Yes ☐ No	Liver Function			
Date//	Date/			
Fibrosis Stage □ 0 □ 1 □ 2 □ 3 □ 4	Total Protein g/L Albumin : g/L			
Inflammatory Grade □ 0 □ 1 □ 2 □ 3 □ 4	ALTumol/L			
	GGTU/L ALP:U/L			
Previous FibroScan [®] □ No □ Yes→Number of scans	Haematology			
Date/ / (of the most recent fibroscan) Result	Haemoglobin g/L Plateletsx 10 ⁹ /L			
rtesuit	INR			
Comorbidities	Clinician Assessment of Liver Scanning			
 ☐ Hepatitis B ☐ Hepatitis C ☐ NASH ☐ Alcohol ☐ IDDM / NIDDM ☐ Cystic Fibrosis ☐ Other 	 □ No / Minimal (F0-1) □ Moderate (F2-3) □ Severe / Cirrhosis (F4) 			
<u>Clinical Notes</u>				

(Block Letters Please)

Referred By:		Report Copies To:		
Referring Dr Address:		Address for Copies:		
Signatura	_	Doto //		Drovidor No
Signature		Date		Provider No
Practice Location:				
Country of Birth:				
•				
Identify as Aboriginal and/or	r rorres sua	ait Islander: □Yes □No		
Height: cm				
Weight: kg				
ВМІ:				
Risk factors for Hepatitis IDU – Current (<6 months):	☐ Yes		□ No	
IDU – Past (>6 months):	□ Yes		□No	
Vertical / Early Horizontal:	☐ Yes		☐ No	
Sexual – MSM:	☐ Yes		☐ No	
Sexual – Non MSM:	☐ Yes		☐ No	
Other (specify):				
(_
Alcohol				
Standard drinks per week:				
		Fibroscan Operator Comme	 nts:	
Features of Decompensation	า			
Ascites:				
Encephalopathy:	No			

PLEASE NOTE: FIBROSCAN® IS AN INVESTIGATIONAL DEVICE AND DOES NOT HAVE PROVEN EQUIVALENCE TO LIVER BIOPSY IN THE ASSESSMENT OF HEPATIC FIBROSIS.

FibroScan® is an ultrasound like device providing an estimation of hepatic fibrosis. The results of FibroScan® need to be interpreted in conjunction with the patient's clinical circumstances. FibroScan® should be repeated when results are discordant with clinical context and consideration for liver biopsy should be given when discordance is explained.

Please note that FibroScan® is an investigational device and does not have proven equivalence to liver biopsy in the assessment of hepatic fibrosis. FibroScan® does not replace conventional liver ultrasound and is not intended for the investigation or exclusion of liver lesions or biliary tract disease.

There is no requirement to fast or alter medication use prior to undergoing FibroScan[®]. FibroScan[®] assessment may not be possible in up to one-quarter of patients with a BMI > 30 kg/m2 and alternative investigations may be appropriate.

For more information regarding use of FibroScan® or the interpretation of results, please contact: Victorian Infectious Diseases Service, the Royal Melbourne Hospital on 9342 7212.